Bain Capital Public Equity Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bain Capital Public Equity Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-59,389	Closed	-$5.59M	–	67
2018 Q2	$5.59M	Sell	59,389 -26,963	-31%	-$2.36M	0.38%	41
2018 Q1	$7M	Sell	86,352 -305,224	-78%	-$26.2M	0.51%	40
2017 Q4	$34.9M	Buy	391,576 +147,531	+60%	+$12.8M	2.54%	10
2017 Q3	$22.7M	Buy	+244,045	New	+$21.6M	1.43%	25

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bain Capital Public Equity Management's BMRN Position: Q3 2018 in Review

Bain Capital Public Equity Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 59,389 shares — an estimated $5.59M sold.

Bain Capital Public Equity Management first reported a position in BMRN in Q3 2017 and held it in 4 quarters. The position peaked at $34.9M in Q4 2017. 460 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Bain Capital Public Equity Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bain Capital Public Equity Management sold 59,389 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $5.59M.
Bain Capital Public Equity Management first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 4 quarters.
Bain Capital Public Equity Management's BioMarin Pharmaceuticals position peaked at $34.9M in Q4 2017.
460 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.